Unit V Literature Review

Research Conducted at Kanazawa University Has Provided New Information about Lung Cancer (Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer)

Obesity, Fitness & Wellness Week . (Nov. 25, 2017): p622.

Copyright: COPYRIGHT 2017 NewsRX LLC

http://www.newsrx.com/newsletters/Obesity,-Fitness-and-Wellness-Week.html

Listen

Full Text: 

2017 NOV 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Lung Cancer have been published. According to news reporting originating from Ishikawa, Japan, by NewsRx correspondents, research stated, "Fibroblast growth factor receptor 1 (FGFR1) amplification has been identified in 10-20% of patients with squamous non small-cell lung cancer. Preclinical models showed promising activity of specific FGFR inhibitors, but early clinical trials showed that only a small fraction of patients with FGFR1-amplified lung cancer responded to FGFR inhibitors."

Our news editors obtained a quote from the research from Kanazawa University, "These unsatisfactory results were partly explained by heterogeneous amplicons around the 8p11 genomic region, leading to false positive amplification results. Furthermore, discrepancies in the gene amplification and protein expression of FGFR1 were also reported. In this study, we identified the roles of alternative receptor tyrosine kinases (RTKs) in FGFR1-amplified lung cancer. These alternative RTKs dominantly activate phosphoinositide 3-kinase-AKT signaling and also mitigate sustained inhibition of mitogen-activated protein kinase signaling by FGFR inhibitors. The rebound activation of extracellular signal regulated kinase phosphorylation was associated with sensitivity to the drugs. Combinatorial inhibition of alternative RTKs and FGFR1 was required to suppress both AKT and extracellular signal-regulated kinase phosphorylation and to induce key pro-apoptotic proteins BIM and p53 upregulated modulator of apoptosis (PUMA). Furthermore, even in FGFR inhibitor-sensitive NCI-H1581 lung cancer cells, MET-expressing clones were already detectable at a very low frequency before resistance induction. Selection of these pre-existing subclones resulted in FGFR inhibitor resistance because of the activation of AKT and extracellular signal-regulated kinase by MET signaling that was mediated by GRB2 associated binding protein 1 (GAB1). These results suggest that incomplete suppression of key survival signals led to intrinsic and acquired resistance to FGFR inhibitors."

According to the news editors, the research concluded: "Our results may help explain the low clinical response rates to FGFR inhibitors in FGFR1-amplified lung cancer."

For more information on this research see: Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer. Carcinogenesis, 2017;38(11):1063-1072. Carcinogenesis can be contacted at: Oxford Univ Press, Great Clarendon St, Oxford OX2 6DP, England. (Oxford University Press - www.oup.com/; Carcinogenesis - carcin.oxfordjournals.org)

The news editors report that additional information may be obtained by contacting H. Ebi, Kanazawa University, Inst Frontier Sci Initiat, Kanazawa, Ishikawa 9201192, Japan. Additional authors for this research include K. Watanabe, K. Kita, H. Kitai, H. Kotani, Y. Sato, N. Inase, S. Yano and Y. Adachi.

The direct object identifier (DOI) for that additional information is: https://doi-org.libraryresources.columbiasouthern.edu/10.1093/carcin/bgx091. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Ishikawa, Japan, Asia, Enzymes and Coenzymes, Aromatic Amino Acids, Tyrosine Kinase, Lung Neoplasms, Lung Cancer, Proteomics, Proteins, Oncology, Kanazawa University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

The citation for this news report is: NewsRx. Research Conducted at Kanazawa University Has Provided New Information about Lung Cancer (Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer). Obesity, Fitness & Wellness Week. November 25, 2017; p 622.

Source Citation   (MLA 8th Edition)

"Research Conducted at Kanazawa University Has Provided New Information about Lung Cancer (Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer)." Obesity, Fitness & Wellness Week, 25 Nov. 2017, p. 622. Health Reference Center Academic, http://link.galegroup.com/apps/doc/A514960580/HRCA?u=oran95108&sid=HRCA&xid=4d710bed. Accessed 9 Dec. 2017.